Program
BRD4 Degrader MT-4561
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Tanabe Pharma.
Furthest: phase 2, since Mar 28, 20251 company-led study, 1 open or runningNext primary completion: Aug 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tanabe Pharma | 11 open or running | phase 2since Mar 28, 2025 | Mar 28, 2025 | Aug 2028phase 2 · NCT06943521 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 28, 2025First study: phase 2 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT06943521 · 27 planned · United States, Japan
Ahead
- Aug 2028Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06943521
TargetBeta
BRD4 →read by rule
“A degrader of bromodomain-containing protein 4 (BRD4), ”NCIt, by rule
Other programs on BRD4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pelabresibrule | Novartis | phase 3 | 11 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06943521Squamous Cell Carcinoma of Head and Neck · United States, Japan | 2 | Recruiting | Aug 2028 | 27 |
How it is read
Names in the registry
- “MT-4561”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.